Introduction {#s1}
============

Behavioral and psychologic symptoms of dementia (BPSD) is the collective term for a group of noncognitive symptoms experienced in persons with dementia. It encompasses symptoms such as agitation, delusions, hallucinations, wandering, and mood disturbances, and is estimated to affect up to 60% of persons with dementia dwelling in the community[@i2168-9709-6-5-215-b01] and 80% of those who are institutionalized.[@i2168-9709-6-5-215-b02],[@i2168-9709-6-5-215-b03] Unfortunately, the paucity of evidence for an effective yet safe treatment for BPSD in dementia complicates the management of these patients. Although antipsychotics have been widely used to manage BPSD, with trials and meta-analyses suggesting modest benefit from these agents compared with placebo, no such treatment has been approved by the US Food and Drug Administration (FDA) thus far.[@i2168-9709-6-5-215-b04]-[@i2168-9709-6-5-215-b06] In 2003 and 2004, initial warnings were issued by the FDA and the UK Committee on Safety of Medicines after pooled data across randomized controlled trials (RCTs) of certain atypical antipsychotics (mainly olanzapine and risperidone) demonstrated an increased risk of cerebrovascular adverse events.[@i2168-9709-6-5-215-b07],[@i2168-9709-6-5-215-b08] In April 2005, the FDA mandated a black box warning regarding an increased risk of mortality in elderly patients treated with atypical antipsychotics for dementia-related psychosis.[@i2168-9709-6-5-215-b09] Subsequently, two observational epidemiologic studies suggested that conventional antipsychotics may confer an even higher risk of death compared with atypical agents,[@i2168-9709-6-5-215-b10],[@i2168-9709-6-5-215-b11] and a further review of the information led the FDA to extend this boxed warning to all antipsychotics in 2008, although methodologic limitations precluded any conclusion that conventional antipsychotics are associated with an increased risk of mortality versus atypical antipsychotics.[@i2168-9709-6-5-215-b12] Mortality risks reported in various publications still vary considerably and lack consistency to allow direct comparison between individual antipsychotics. This review aims to provide an updated overview of the publications available on mortality data and risks associated with antipsychotic dose and duration of use. Confounders and limitations will be discussed to allow clinicians to better make judgment calls on assessing risks and benefits when treating BPSD with an antipsychotic.

Methods {#s2}
=======

Literature searches were conducted through PubMed and Ovid/MEDLINE. Keyword terms searched were *dementia*, *mortality*, *death*, *elderly*, *geriatric*, *antipsychotics*, *behavioral and psychologic symptoms of dementia*, and *BPSD*. All searches were limited to humans, published between January 2005 and June 2015, and written in the English language. Some articles, as identified in [Tables 1](#i2168-9709-6-5-215-t01){ref-type="table"} through [3](#i2168-9709-6-5-215-t03){ref-type="table"}, that studied the elderly population without a diagnosis of dementia, and were obtained from this literature search, were included to facilitate discussion within this article.

###### 

Mortality data and risks associated with antipsychotic use

![](i2168-9709-6-5-215-t01)

###### 

Mortality risk associated with antipsychotic dose

![](i2168-9709-6-5-215-t02)

###### 

Mortality risk associated with the antipsychotic duration of use

![](i2168-9709-6-5-215-t03)

Mortality Data {#s3}
==============

Findings from internal FDA data in 2005, which reviewed a total of 17 placebo-controlled trials (7 trials for risperidone, 5 for olanzapine, 3 for aripiprazole, and 2 for quetiapine) in the elderly (n = 5106) with BPSD, revealed an approximately 1.6- to 1.7-fold increase in mortality for patients on an atypical antipsychotic compared with placebo. Most deaths were attributed to cardiac-related events, such as heart failure and sudden death, or infections (mainly pneumonia). Based on this information, the FDA concluded that the mortality risk is probably related to the common pharmacologic effects of all atypical antipsychotic medications, including those that have not been studied in the dementia population.[@i2168-9709-6-5-215-b09]

[Table 1](#i2168-9709-6-5-215-t01){ref-type="table"} represents the findings of key publications available on mortality data and risks associated with antipsychotic use. Wang et al[@i2168-9709-6-5-215-b13] presented evidence indicating that conventional antipsychotics are at least as likely to cause an increased risk of death in the elderly compared with atypical antipsychotics. In fact, figures reported pointed to a higher mortality risk with conventional antipsychotics than atypical antipsychotics at all time points studied, regardless of whether dementia was present and whether the patient resided in a nursing facility. Likewise, a study conducted by Gill et al[@i2168-9709-6-5-215-b10] showed that initiation of an atypical antipsychotic was associated with a higher risk of death versus no antipsychotic use, and the initiation of a conventional antipsychotic seemed to demonstrate a marginally higher mortality. A meta-analysis by Schneider et al[@i2168-9709-6-5-215-b14] reported a 1% increase in absolute mortality risk in patients with dementia with the use of an atypical antipsychotic relative to placebo, but a sensitivity analysis performed did not point to individual drugs having different risks. However, Kales et al[@i2168-9709-6-5-215-b15] estimated that individual antipsychotics may be associated with different mortality risks, the highest observed with haloperidol and the lowest with quetiapine, compared with a nonantipsychotic. In line with these findings were those presented by Rochon et al[@i2168-9709-6-5-215-b16] suggesting that the initiation of a conventional antipsychotic may be associated with a higher occurrence of any serious adverse event leading to hospitalization or death, compared with an atypical antipsychotic in community-dwelling and nursing home elderly with dementia. Furthermore, retrospective cohort studies in the elderly[@i2168-9709-6-5-215-b17],[@i2168-9709-6-5-215-b18] supported findings that haloperidol had a higher risk of mortality compared with atypical antipsychotics. More recently, Maust et al[@i2168-9709-6-5-215-b19] also observed that individuals receiving haloperidol had the greatest risk of mortality, followed by those receiving risperidone, olanzapine, and quetiapine.

A meta-analysis performed by Tan et al[@i2168-9709-6-5-215-b20] suggested that individually, risperidone was significantly associated with increased incidence of stroke, but this effect was not seen with aripiprazole, olanzapine, or quetiapine. Although the general trend of these studies points to quetiapine as having the lowest risk and haloperidol having the highest mortality risk, a recent review by Hulshof et al[@i2168-9709-6-5-215-b21] seems to suggest otherwise. Elderly on conventional antipsychotics did not seem to demonstrate an increased mortality risk. Likewise, when the meta-analysis was repeated using only trials involving haloperidol, the risk difference and risk ratios were not statistically significant. It should be noted, however, that the data were pooled from RCTs in the geriatric population with dementia, delirium, or a high risk of delirium.

Dose Relation {#s4}
=============

Few observational studies ([Table 2](#i2168-9709-6-5-215-t02){ref-type="table"}) have reported that the mortality risk associated with antipsychotic use in the elderly[@i2168-9709-6-5-215-b13],[@i2168-9709-6-5-215-b17] and the elderly with dementia[@i2168-9709-6-5-215-b19] may have a dose-dependent effect. Wang et al[@i2168-9709-6-5-215-b13] reported an increased risk of death with a high-dose conventional antipsychotic versus a low-dose conventional antipsychotic relative to an atypical antipsychotic. Gerhard et al[@i2168-9709-6-5-215-b17] found a dose-dependent change in risk of non--cancer-related death for haloperidol, risperidone, and olanzapine, but not with high-dose quetiapine. Additionally, Maust et al[@i2168-9709-6-5-215-b19] reported that atypical antipsychotics as a group displayed a higher mortality in the high-dose group compared with the low-dose group. The increased mortality risk was not statistically significant for the medium-dose group compared with the low-dose group.

Duration of Use {#s5}
===============

As presented in [Table 3](#i2168-9709-6-5-215-t03){ref-type="table"}, most of the studies have reported that an increased risk of death seemed to climb shortly upon antipsychotic initiation, which may change with the continued use of the antipsychotic.[@i2168-9709-6-5-215-b10],[@i2168-9709-6-5-215-b13],[@i2168-9709-6-5-215-b15],[@i2168-9709-6-5-215-b22] The observed temporal relationship, however, did not appear to be consistent among studies[@i2168-9709-6-5-215-b23] and ranged from 30 days up until the end of the study duration of 180 days.[@i2168-9709-6-5-215-b10] Wang et al[@i2168-9709-6-5-215-b13] reported a higher mortality risk with conventional antipsychotics relative to atypical antipsychotics at all time points studied. Using risperidone as a comparator, Kales et al[@i2168-9709-6-5-215-b15] found the relative risk of death for haloperidol to be greatest within 30 days of initiation but dropped drastically and was not statistically significant between 90 and 120 days. The risk of death for atypical antipsychotics was greater on average during the first 120 days of use, compared with the period between 120 and 180 days. Interestingly, Kleijer et al[@i2168-9709-6-5-215-b22] suggested the risk of cerebrovascular adverse events was found to be much higher within 1 week of antipsychotic initiation but decreased to its baseline after 3 months of use. In contrast, Ballard et al[@i2168-9709-6-5-215-b23] found mortality rate to rise over time for the group assigned to continue antipsychotic treatment compared with those assigned to switch to a placebo.

Limitations {#s6}
===========

Despite having numerous studies and meta-analyses published on this subject matter, many of the findings still require careful interpretation. Most of the studies were retrospective cohort studies, and data from such cohort studies are observational in nature. The lack of randomization makes it tough to eliminate confounders. The early discontinuation of treatment,[@i2168-9709-6-5-215-b10],[@i2168-9709-6-5-215-b15] presence of terminal illnesses,[@i2168-9709-6-5-215-b21] unreported causes of death,[@i2168-9709-6-5-215-b10] and comorbid delirium[@i2168-9709-6-5-215-b21] likewise contribute to confounding factors in reported trials. Meta-analyses were often limited by underreporting of less common adverse events in the individual trials.[@i2168-9709-6-5-215-b14],[@i2168-9709-6-5-215-b20] Moreover, publication bias may also result in important figures being omitted. The paucity of data on antipsychotics with a lower usage, such as aripiprazole, ziprasidone, and some conventional antipsychotics, makes it difficult to conclude which agents are comparatively safer. Other limitations encountered included unclear baseline differences of the study population, insufficient blinding, and absence of clear details on the methods of blinding.[@i2168-9709-6-5-215-b21] One meta-analysis included trials that excluded individuals taking psychotropic medications as well as trials that allowed individuals on psychotropics, such as cholinesterase inhibitors and other drugs.[@i2168-9709-6-5-215-b20] In spite of the progressive nature of the disease, many studies did not account for the severity of dementia and lacked details on the symptoms of behavior or psychiatric illness,[@i2168-9709-6-5-215-b17],[@i2168-9709-6-5-215-b19]-[@i2168-9709-6-5-215-b21] although analyses suggested a relationship between mortality and some neuropsychiatric symptoms.[@i2168-9709-6-5-215-b19] In studies using data derived from prescriptions, the presence of occasional as-needed use and varying titration schedules across agents may also contribute to the potential for misclassification.[@i2168-9709-6-5-215-b17],[@i2168-9709-6-5-215-b18] Finally, not all studies reviewed in this manuscript conform to the diagnosis of BPSD, and some studies focused on the elderly population without a diagnosis of dementia.

Conclusion {#s7}
==========

Available data on the safety of antipsychotics in BPSD management suggests that antipsychotics are indeed associated with elevated risks of cerebrovascular adverse events and mortality. There is also evidence suggestive of the mortality risk varying among individual agents, with haloperidol having a higher risk of mortality compared with risperidone, olanzapine, and quetiapine.[@i2168-9709-6-5-215-b17]-[@i2168-9709-6-5-215-b19] Using a high-dose rather than a low-dose atypical antipsychotic (eg, risperidone 3 mg versus 0.5 mg) may be associated with additional mortality.[@i2168-9709-6-5-215-b19] The risk of death with haloperidol and atypical antipsychotics is greatest within 30 days and up to 120 days of initiation, respectively, and tends to decrease thereafter,[@i2168-9709-6-5-215-b15] which may be a true reflection of how antipsychotics are used in the community setting. In view of the associated risks, it is prudent to consider the lowest effective dose for the shortest duration, keeping in mind the confounders and limitations discussed above. To help practitioners use antipsychotics safely for BPSD management, the Centers for Medicare and Medicaid Services issued a set of guidelines[@i2168-9709-6-5-215-b24] to highlight principles in dementia care, such as the timeframe to reassess the need for an antipsychotic agent. It is important to note, however, that these findings are mainly for patients with dementia. Antipsychotics are still indicated in geriatric patients who receive a diagnosis of schizophrenia, bipolar disorder, or other major psychiatric diagnoses.[@i2168-9709-6-5-215-b25]
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